Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2013
11/19/2013US8586094 Coated tablets
11/19/2013US8586093 Pulmonary delivery for levodopa
11/19/2013US8586091 Pharmaceutical composition comprising N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-quinazolinamine
11/19/2013US8586088 Tamper-resistant oral opioid agonist formulations
11/19/2013US8586084 Modified release compositions comprising tacrolimus
11/19/2013US8586082 Solid orally administerable pharmaceutical dosage forms with rapid active principle release
11/19/2013US8586076 Compositions comprising dietary fat complexer and methods for their use
11/19/2013US8586068 Insect attractants and their use in methods of insect control
11/19/2013US8586066 Topical antifungal composition
11/19/2013US8586064 Treating eczema and/or psoriasis
11/19/2013US8586061 Multiple unit dosage form having a therapeutic agent in combination with a nutritional supplement
11/19/2013US8586020 Poly(organophosphazene) composition for biomaterials
11/19/2013US8586019 Conjugates of polymers having a therapeutically active agent and an angiogenesis targeting moiety attached thereto and uses thereof in the treatment of angiogenesis related diseases
11/19/2013US8586018 Thin films for controlled protein interaction
11/19/2013US8586010 Dapsone to treat rosascea
11/19/2013US8586008 Pharmaceutical foam
11/19/2013US8585938 UV-absorbers for ophthalmic lens materials
11/19/2013CA2786802C Composition for exterminating animal parasite comprising an aromatic carboxamide derivative and method thereof
11/19/2013CA2786330C A pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one with improved storage and solubility properties
11/19/2013CA2771188C Passive solid tumor-targeted pectin-doxorubicin prodrug and preparation method thereof
11/19/2013CA2746307C Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors
11/19/2013CA2740530C Independent, tobacco addiction-dispelling and detoxifying filter rod and cigarette holder, and process for manufacturing the same
11/19/2013CA2739888C Spirocyclic gpr40 modulators
11/19/2013CA2736117C Compounds, compositions and methods of using same for modulating uric acid levels
11/19/2013CA2722050C Polymerized micelles
11/19/2013CA2711414C Oral care product and methods of use and manufacture thereof
11/19/2013CA2707418C Inhibitors of human immunodeficiency virus replication
11/19/2013CA2692922C Azaindole-indole coupled derivatives, preparation methods and uses thereof
11/19/2013CA2681267C Anti-angiogenic agents and methods of use
11/19/2013CA2678956C Method of determining the weight of the coating to be applied to form a controlled release dosage form
11/19/2013CA2677588C Use of condensed pyrimidine derivatives for the treatment of autoimmune and inflammatory diseases
11/19/2013CA2671857C 2-piperazin-1-yl-3h-imidazo[4,5-b]pyridine derivatives
11/19/2013CA2649173C Azaheterocyclyl derivatives of androstanes and androstenes as medicaments for cardiovascular disorders
11/19/2013CA2645110C Pharmaceutical composition for external use
11/19/2013CA2640997C Doxorubicin formulations for anti-cancer use
11/19/2013CA2633624C 3,5-substituted piperidine compounds as renin inhibitors
11/19/2013CA2632899C Biphenyl derivatives as selective agonists of gamma rar receptors
11/19/2013CA2622472C Dipeptidyl peptidase inhibitors for treating diabetes
11/19/2013CA2618340C Piperidine and piperazine derivatives as p2x3 antagonists
11/19/2013CA2614627C Methods and compositions for treating ophthalmic conditions via serum retinol, serum retinol binding protein (rbp), and/or serum retinol-rbp modulation
11/19/2013CA2613976C New pharmaceutical compositions containing hyaluronic acid and collagenase for the topical treatment of wounds, burns and ulcers
11/19/2013CA2611914C Use of a combination comprising l-carnitine or alkanoyl l-carnitine, lipid soluble benzoquinone and omega-3-polyunsaturated fatty acid for the preparation of a dietary supplement or medicament for the treatment of corneal diseases
11/19/2013CA2611140C Compositions and methods for enhancing nitric oxide delivery
11/19/2013CA2609062C Oligonucleotides or their functional homologues, a composition comprising the same and a method of treating b cell neoplasm
11/19/2013CA2608629C Orally disintegrating powder comprising cilostazol and mannitol
11/19/2013CA2603030C Benzyloxypropylamine derivative
11/19/2013CA2602750C Pharmaceutical preparation of n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide
11/19/2013CA2595889C N-halogenated amino acids and n,n-dihalogenated amino acids in combination with hypohalous acids
11/19/2013CA2595633C Synthetic sealants
11/19/2013CA2595043C Use of oxycodone for treating visceral pain
11/19/2013CA2591991C Triazolophthalazines
11/19/2013CA2587423C 1-arylpyrazoles and their use as pesticides
11/19/2013CA2581224C Targeting opposite strand replication intermediates of single-stranded viruses by rnai
11/19/2013CA2580491C 4-((phenoxyalkyl)thio)-phenoxyacetic acid derivatives and use thereof as ppar modulators
11/19/2013CA2577273C Fumarate of 4-((4-((4-(2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile
11/19/2013CA2572380C Gemcitabine derivatives nanoparticles
11/19/2013CA2570698C Bis(thio-hydrazide amide) salts for treatment of cancers
11/19/2013CA2565067C Intraocular implants of alpha-2 adrenergic receptor agonists and methods for improving vision
11/19/2013CA2559650C Sns-595 and methods of using the same
11/19/2013CA2539403C 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
11/19/2013CA2532802C Antibiotic compound isolated from streptomyces sp
11/19/2013CA2515929C Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions
11/19/2013CA2497582C Prophylaxis and treatment of infectious diseases
11/19/2013CA2496213C Metalloprotease activation of myostatin, and methods of modulating myostatin activity
11/19/2013CA2457356C Canine cardiac diet
11/19/2013CA2446620C Antiviral nucleosides
11/19/2013CA2404890C Rna sequence-specific mediators of rna interference
11/19/2013CA2398083C Nphs2 gene involved in the cortico-resistant neprhotic syndrome, protein encoded by said gene and diagnostic and therapeutic uses
11/19/2013CA2353866C Treatment of papillomavirus infections
11/19/2013CA2329757C Use of .alpha.1.beta.1 integrin receptor inhibitors and tgf-.beta.1 inhibitors in the treatment of kidney disease
11/19/2013CA2290220C An infectious cdna clone of north american porcine reproductive and respiratory syndrome (prrs) virus and uses thereof
11/15/2013CA2815477A1 Pharmaceutical composition
11/14/2013WO2013170191A1 Methods of using antagonists of nad biosynthesis from nicotinamide
11/14/2013WO2013170189A1 Combination of beta - hydroxy - beta - methylbutyrate and beta - alanine for increasing muscle blood flow
11/14/2013WO2013170186A1 Carbazole-containing sulfonamides as cryptochrome modulators
11/14/2013WO2013170182A1 Treating cancer with an hsp90 inhibitory compound
11/14/2013WO2013170165A1 Antibacterial agents
11/14/2013WO2013170159A1 Treating cancer with hsp90 inhibitory compounds
11/14/2013WO2013170147A1 Compounds useful for promoting protein degradation and methods using same
11/14/2013WO2013170142A1 Solid state forms of fidaxomycin and processes for preparation thereof
11/14/2013WO2013170118A1 Thiazolecarboxamide derivatives for use as nampt inhibitors
11/14/2013WO2013170115A1 Pyridazine and pyridine derivatives as nampt inhibitors
11/14/2013WO2013170113A1 Nampt inhibitors
11/14/2013WO2013170112A1 Nampt inhibitors
11/14/2013WO2013170072A2 Compounds for the treatment of neurological disorders
11/14/2013WO2013170069A1 Medicament, method, and drug delivery device for treatment of ovarian cancer
11/14/2013WO2013170030A1 Antibacterial agents
11/14/2013WO2013170006A2 Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors
11/14/2013WO2013169989A1 Method and compounds for inhibiting the mcm complex and their application in cancer treatment
11/14/2013WO2013169979A2 Polymorph compositions, methods of making, and uses thereof
11/14/2013WO2013169964A1 Heteroaryl compounds and methods of use thereof
11/14/2013WO2013169939A2 New methods
11/14/2013WO2013169936A2 Compositions and methods for treating cardiac hypertrophy
11/14/2013WO2013169925A1 Novel formulations of nitrofurans including nifurtimox with enhanced activity with lower toxicity
11/14/2013WO2013169907A1 Alpha 7 nicotinic acetylcholine allosteric modulators, their derivatives and uses thereof
11/14/2013WO2013169889A1 Alpha 7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof
11/14/2013WO2013169879A1 Coated medical devices comprising a water - insoluble therapeutic agent and an additive
11/14/2013WO2013169864A2 TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORƴ AND THE TREATMENT OF DISEASE
11/14/2013WO2013169860A1 Fumigillol type compounds and methods of making and using same
11/14/2013WO2013169857A1 Treating hypothalamic obesity with metap2 inhibitors
1 ... 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 ... 7860